Hoe verhoudt KDNY's PB Ratio zich tot zijn concurrenten?

KDNY is duur op basis van de Price-To-Book -ratio ( 8.1 x) vergeleken met het gemiddelde van de peer ( 4.8 x).

Hoe verhoudt KDNY's PB Ratio zich tot andere bedrijven in de US Biotechs industrie?

KDNY is duur op basis van de Price-To-Book -ratio ( 8.1 x) vergeleken met het US Biotechs -industriegemiddelde ( 1.9 x).

Wat is KDNY's PB Ratio vergeleken met zijn Fair PB Ratio? Dit is de verwachte PB Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

Onvoldoende gegevens om de Price-To-Book Fair Ratio van { KDNY te berekenen voor waarderinganalyse.

Wat is de reële prijs van KDNY als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

Onvoldoende gegevens om de reële waarde van KDNY te berekenen voor waarderingsanalyse.

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

De koersdoelstelling is lager dan de huidige aandelenkoers.

Chinook Therapeutics (Nasdaq:KDNY) - Aandelenkoers, Nieuws & Analyse

KDNY Overzicht aandelen

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. Meer informatie

KDNY fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 63.8% per jaar groeien

Risicoanalyse

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Aandeelhouders zijn het afgelopen jaar verwaterd

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Chinook Therapeutics, Inc. Concurrenten

Catalyst Pharmaceuticals

NasdaqCM:CPRX

US$2.5b

Turning Point Therapeutics

NasdaqGS:TPTX

US$3.8b

Janux Therapeutics

NasdaqGM:JANX

US$2.4b

Recursion Pharmaceuticals

NasdaqGS:RXRX

US$1.6b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Chinook Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$40.39
52 Week Hoogtepunt	US$40.51
52 Week Laag	US$18.34
Bèta	0.67
11 maand verandering	2.98%
3 maanden verandering	72.68%
1 Jaar Verandering	95.69%
33 jaar verandering	n/a
5 jaar verandering	n/a
Verandering sinds IPO	173.46%

Recent nieuws en updates

Recent updates

Will Chinook Therapeutics (NASDAQ:KDNY) Spend Its Cash Wisely?

May 28

Companies Like Chinook Therapeutics (NASDAQ:KDNY) Are In A Position To Invest In Growth

Feb 14

Chinook Therapeutics: Multiple Shots On Goal For IgAN

Aug 31

Analysts Have Just Cut Their Chinook Therapeutics, Inc. (NASDAQ:KDNY) Revenue Estimates By 17%

Aug 12

Chinook Therapeutics GAAP EPS of -$0.61 in-line, revenue of $0.42M in-line

Aug 08

Chinook gets European orphan drug designation for BION-1301 for a type of kidney disease

Jul 05

Rendement voor aandeelhouders

	KDNY	US Biotechs	US Markt
7D	0.3%	2.4%	2.2%
1Y	95.7%	16.2%	31.7%

Rendement versus industrie: KDNY overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 16.2 % opleverde.

Rendement versus markt: KDNY overtrof de US markt, die het afgelopen jaar een rendement opleverde van 31.7 %.

Prijsvolatiliteit

Is KDNY's price volatile compared to industry and market?
KDNY volatility
KDNY Average Weekly Movement	17.1%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van KDNY is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van KDNY is het afgelopen jaar gestegen van 10% naar 17%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
n/a	214	Eric Dobmeier	www.chinooktx.com

Chinook Therapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Chinook Therapeutics zich tot de beurswaarde?
KDNY fundamentele statistieken
Marktkapitalisatie	US$2.90b
Inkomsten(TTM)	-US$245.65m
Inkomsten(TTM)	US$5.85m

495.8x

P/S-verhouding

-11.8x

Koers/Winstverhouding

Is KDNY overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
KDNY resultatenrekening (TTM)
Inkomsten	US$5.85m
Kosten van inkomsten	US$193.72m
Brutowinst	-US$187.87m
Overige uitgaven	US$57.79m
Inkomsten	-US$245.65m

Laatst gerapporteerde inkomsten

Jun 30, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-3.42
Brutomarge	-3,211.95%
Nettowinstmarge	-4,199.93%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde KDNY op de lange termijn?

Bekijk historische prestaties en vergelijking

KDNY Overzicht aandelen

Beloningen

Risicoanalyse

Chinook Therapeutics, Inc. Concurrenten

NasdaqCM:CPRX

US$2.5b

NasdaqGS:TPTX

US$3.8b

NasdaqGM:JANX

US$2.4b

NasdaqGS:RXRX

US$1.6b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Novartis AG (SWX:NOVN) completed the acquisition of Chinook Therapeutics, Inc. (NasdaqGS:KDNY) from a group of shareholders.

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from NASDAQ Biotechnology Index

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from S&P TMI Index

Second quarter 2023 earnings released: US$0.94 loss per share (vs US$0.61 loss in 2Q 2022)

Chinook Therapeutics, Inc. Announces the First Patient Enrolled in its Phase 3 Second Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy

Chinook Therapeutics, Inc. Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failure Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress

Recent updates

Novartis AG (SWX:NOVN) completed the acquisition of Chinook Therapeutics, Inc. (NasdaqGS:KDNY) from a group of shareholders.

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from NASDAQ Biotechnology Index

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from S&P TMI Index

Second quarter 2023 earnings released: US$0.94 loss per share (vs US$0.61 loss in 2Q 2022)

Chinook Therapeutics, Inc. Announces the First Patient Enrolled in its Phase 3 Second Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy

Chinook Therapeutics, Inc. Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failure Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress

Price target increased by 7.8% to US$39.45

Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress

New major risk - Share price stability

Will Chinook Therapeutics (NASDAQ:KDNY) Spend Its Cash Wisely?

Consensus revenue estimates increase by 36%

Consensus revenue estimates increase by 273%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

President notifies of intention to sell stock

Independent Lead Director recently sold US$6.1m worth of stock

Chief Scientific Officer exercised options and sold US$57k worth of stock

Consensus revenue estimates increase by 27%, EPS downgraded

Full year 2022 earnings: EPS and revenues exceed analyst expectations

President exercised options and sold US$192k worth of stock

Chinook Therapeutics, Inc. Appoints Andrew Oxtoby as Chief Commercial Officer

Companies Like Chinook Therapeutics (NASDAQ:KDNY) Are In A Position To Invest In Growth

President recently sold US$190k worth of stock

Chief Scientific Officer exercised options and sold US$191k worth of stock

Chief Operating Officer exercised options and sold US$246k worth of stock

President exercised options and sold US$657k worth of stock

Consensus forecasts updated

Chief Operating Officer notifies of intention to sell stock

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Chief Operating Officer exercised options and sold US$217k worth of stock

Chinook Therapeutics, Inc. Presents Updated Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort, Preclinical Atrasentan Research and Ongoing Clinical Trials at the American Society of Nephrology (ASN) Kidney Week 2022

Chief Operating Officer exercised options and sold US$145k worth of stock

Independent Director recently bought US$212k worth of stock

Chinook Therapeutics: Multiple Shots On Goal For IgAN

Consensus revenue estimates fall by 14%

Analysts Have Just Cut Their Chinook Therapeutics, Inc. (NASDAQ:KDNY) Revenue Estimates By 17%

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Chinook Therapeutics GAAP EPS of -$0.61 in-line, revenue of $0.42M in-line

Chief Scientific Officer exercised options and sold US$98k worth of stock

Chief Scientific Officer exercised options and sold US$89k worth of stock

Chinook gets European orphan drug designation for BION-1301 for a type of kidney disease

High number of new directors

President recently bought US$65k worth of stock

Consensus forecasts updated

Price target increased to US$34.86

Chinook Therapeutics, Inc. Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and Evotec Collaboration at 59th European Renal Association Congress 2022

Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and from Atrasentan Preclinical Mechanism of Action Studies at the 59th European Renal Association (ERA) Congress 2022

High number of new directors

Chinook Therapeutics, Inc., Annual General Meeting, May 26, 2022

Chief Scientific Officer exercised options and sold US$75k worth of stock

Chinook Therapeutics Announces Initiation of Phase 1 Healthy Volunteer Trial of CHK-336, a First-in-Class LDHA Inhibitor to Treat Hyperoxalurias

High number of new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Chinook Therapeutics, Inc. Announces Resignation of Alan Glicklich as Chief Medical Officer, Effective February 11, 2022

High number of new directors

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Chinook Therapeutics, Inc. Samenvatting

495.8x